Last updated on May 2018

Study of GNS561 in Patients With Liver Cancer


Brief description of study

This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients with advanced malignancies including hepatocellular carcinoma.

Detailed Study Description

This is a multicenter, open-label, uncontrolled, repeat-dose Phase 1/2a study designed to evaluate the safety profile and to determine the recommended Phase 2 dose of GNS561 in patients with advanced malignancies such as HCC. This study will enroll approximately 50 patients and consists of 2 parts: Phase 1(dose escalation) and Phase 2 (continuation). All patients will be treated until the occurrence of an unacceptable toxicity, disease progression, or withdrawal of consent. In this study a treatment cycle is defined as 4 weeks (28 days). Patients are to take their assigned dose of GNS561, at the same time each Monday, Wednesday and Friday following a meal.

Clinical Study Identifier: NCT03316222

Contact Investigators or Research Sites near you

Start Over

Jules Bordet Institute

Brussel, Belgium
7.22miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.